RET and lung adenocarcinoma: While RET fusions are well-established oncogenic drivers occurring in approximately 1–2% of lung adenocarcinomas, other RET alterations—including point mutations, amplifications, and structural deletions—are much less common, and their oncogenicity and therapeutic relevance remain incompletely characterized (12).